NO924027L - Heterobiarylderivater, legemidler inneholdende disse forbindelser, og fremgangsmaate for deres fremstilling - Google Patents

Heterobiarylderivater, legemidler inneholdende disse forbindelser, og fremgangsmaate for deres fremstilling

Info

Publication number
NO924027L
NO924027L NO92924027A NO924027A NO924027L NO 924027 L NO924027 L NO 924027L NO 92924027 A NO92924027 A NO 92924027A NO 924027 A NO924027 A NO 924027A NO 924027 L NO924027 L NO 924027L
Authority
NO
Norway
Prior art keywords
bond
group
preparation
heterobia
procedures
Prior art date
Application number
NO92924027A
Other languages
English (en)
Other versions
NO924027D0 (no
Inventor
Guenther Linz
Helmut Pieper
Frank Himmelsbach
Volkhard Austel
Thomas Mueller
Johannes Weisenberger
Elke Seewaldt-Becker
Original Assignee
Thomae Gmbh Dr K
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Thomae Gmbh Dr K filed Critical Thomae Gmbh Dr K
Publication of NO924027D0 publication Critical patent/NO924027D0/no
Publication of NO924027L publication Critical patent/NO924027L/no

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
    • C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
    • C07D239/32—One oxygen, sulfur or nitrogen atom
    • C07D239/34—One oxygen atom
    • C07D239/36—One oxygen atom as doubly bound oxygen atom or as unsubstituted hydroxy radical
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D237/00—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings
    • C07D237/02—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings not condensed with other rings
    • C07D237/06—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members
    • C07D237/10—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D237/14—Oxygen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D237/00—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings
    • C07D237/02—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings not condensed with other rings
    • C07D237/06—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members
    • C07D237/10—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D237/20—Nitrogen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D237/00—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings
    • C07D237/02—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings not condensed with other rings
    • C07D237/06—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members
    • C07D237/10—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D237/24—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02—Phosphorus compounds
    • C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
    • C07F9/645—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom having two nitrogen atoms as the only ring hetero atoms
    • C07F9/6509—Six-membered rings
    • C07F9/650905—Six-membered rings having the nitrogen atoms in the positions 1 and 2

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Pyridine Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)

Abstract

Oppfinnelsen angår heterobiarylderivater med den generelle formel R-^H - Xx - X2 - X3 - Y1 - Y2 - Y3 - Y4 - E , (I) hvor R , X til X , Y til Y4 og E har en rekke betydninger, særlig hvor R betyr hydrogen eller alkoksykarbonyl, X betyr en metylen eller -C(=NH)-, X_ betyr fenylen, X betyr en eventuelt substituert pyrimidinylen- eller pyridazinylengruppe, Y betyr en binding, -CO-, -CONH- eller -CONCH3-, Y_ betyr en binding, alkylen eller cykloheksylen, Y betyr en binding, eller en piperidinylengruppe, Y betyr en binding eller metylen, E betyr en karboksygruppe eller en alkoksykarbonylgruppe med tilsammen 2 eller 3 karbonatomer, hvorunder minst en av restene Y , Y , Y_ eller Y ikke utgjør en binding og resten E ikke kan følge umiddelbart etter et heteroatom i restene Y. eller YS, samt deres tautomerer, deres stereoisomerer, deres blandinger og deres salter, spesielt deres fysiologisk akseptable salter med uorganiske eller organiske syrer eller baser, som oppviser verdifulle farmakologiske egenskaper, fortrinnsvis aggregasjonshemmende virkninger. Fremgangsmåter for deres fremstilling er beskrevet.
NO92924027A 1991-10-18 1992-10-16 Heterobiarylderivater, legemidler inneholdende disse forbindelser, og fremgangsmaate for deres fremstilling NO924027L (no)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
DE4134467A DE4134467A1 (de) 1991-10-18 1991-10-18 Heterobiarylderivate, diese verbindungen enthaltende arzneimittel und verfahren zu ihrer herstellung

Publications (2)

Publication Number Publication Date
NO924027D0 NO924027D0 (no) 1992-10-16
NO924027L true NO924027L (no) 1993-04-19

Family

ID=6442941

Family Applications (1)

Application Number Title Priority Date Filing Date
NO92924027A NO924027L (no) 1991-10-18 1992-10-16 Heterobiarylderivater, legemidler inneholdende disse forbindelser, og fremgangsmaate for deres fremstilling

Country Status (13)

Country Link
US (2) US5418233A (no)
EP (1) EP0537696A1 (no)
JP (1) JPH05221992A (no)
KR (1) KR930007913A (no)
AU (1) AU662930B2 (no)
CA (1) CA2080748A1 (no)
DE (1) DE4134467A1 (no)
FI (1) FI924687A (no)
HU (1) HUT62272A (no)
MX (1) MX9205908A (no)
NO (1) NO924027L (no)
NZ (1) NZ244766A (no)
ZA (1) ZA927994B (no)

Families Citing this family (42)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK0567967T3 (da) * 1992-04-28 1996-11-18 Thomae Gmbh Dr K Tritium-mærkede fibrinogen-receptor-antagonister, deres anvendelse og fremgangsmåde til deres fremstilling
US5652242A (en) * 1993-03-29 1997-07-29 Zeneca Limited Heterocyclic derivatives
ZW4194A1 (en) * 1993-03-29 1994-12-21 Zeneca Ltd Heterocyclic compounds
DE69411900T2 (de) * 1993-03-29 1998-12-10 Zeneca Ltd., London Heterozyklische derivate als plätchenaggregationsinhibitoren
US5753659A (en) * 1993-03-29 1998-05-19 Zeneca Limited Heterocyclic compouds
ES2114654T3 (es) * 1993-06-08 1998-06-01 Vertex Pharma Piridazinas como inhibidores de la enzima de conversion de la interleuquina-1beta.
US5463011A (en) * 1993-06-28 1995-10-31 Zeneca Limited Acid derivatives
GB9313285D0 (en) * 1993-06-28 1993-08-11 Zeneca Ltd Acid derivatives
GB9313268D0 (en) * 1993-06-28 1993-08-11 Zeneca Ltd Chemical compounds
IL118631A (en) * 1995-06-27 2002-05-23 Tanabe Seiyaku Co History of pyridazinone and processes for their preparation
DE19605766A1 (de) * 1996-02-16 1997-08-21 Basf Ag Substituierte 2-Phenylpyridine
US6057342A (en) * 1996-08-16 2000-05-02 Dupont Pharmaceutical Co. Amidinophenyl-pyrrolidines, -pyrrolines, and -isoxazolidines and derivatives thereof
WO1998011075A1 (en) * 1996-09-16 1998-03-19 Du Pont Pharmaceuticals Company Pyrazinones and triazinones and their derivatives thereof
DE19652919A1 (de) * 1996-12-19 1998-06-25 Solvay Pharm Gmbh Piperazinophenyl- und Piperazinophenyloxy-carbonsäure-Derivate sowie Verfahren und Zwischenprodukte zu ihrer Herstellung und diese Verbindungen enthaltende Arzneimittel
TWI241295B (en) * 1998-03-02 2005-10-11 Kowa Co Pyridazine derivative and medicine containing the same as effect component
AR029489A1 (es) * 2000-03-10 2003-07-02 Euro Celtique Sa Piridinas, pirimidinas, pirazinas, triazinas sustituidas por arilo, composiciones farmaceuticas y el uso de las mismas para la manufactura de un medicamento
IL154709A0 (en) * 2000-09-18 2003-10-31 Eisai Co Ltd Pyridazinone and triazinone derivatives and pharmaceutical compositions containing the same
AR037233A1 (es) * 2001-09-07 2004-11-03 Euro Celtique Sa Piridinas aril sustituidas, composiciones farmaceuticas y el uso de dichos compuestos para la elaboracion de un medicamento
US6869954B2 (en) 2001-09-26 2005-03-22 Kowa Co., Ltd. Water-soluble phenylpyridazine compounds and compositions containing the same
CA2478283C (en) * 2002-03-12 2010-10-12 Shionogi & Co., Ltd. Process for trans-4-amino-1-cyclohexanecarboxylic acid derivatives
KR100469653B1 (ko) * 2002-08-05 2005-02-02 (주)동서생활건강 모발 컨디셔닝 고형 세정 조성물
US7462613B2 (en) * 2002-11-19 2008-12-09 Sanofi-Aventis Deutschland Gmbh Pyridazinone derivatives as pharmaceuticals and pharmaceutical compositions containing them
US7309701B2 (en) * 2002-11-19 2007-12-18 Sanofi-Aventis Deutschland Gmbh Pyridazinone derivatives as pharmaceuticals and pharmaceutical compositions containing them
FR2847253B1 (fr) * 2002-11-19 2007-05-18 Aventis Pharma Sa Nouveaux derives de pyridazinones a titre de medicaments et compositions pharmaceutiques les renfermant
US8013156B2 (en) * 2003-03-19 2011-09-06 Exelixis, Inc. Tie-2 modulators and methods of use
RU2423351C2 (ru) * 2004-12-16 2011-07-10 Вертекс Фармасьютикалз Инкорпорейтед Пирид-2-оны, применимые как ингибиторы протеинкиназ семейства тес для лечения воспалительных, пролиферативных и иммунологически-опосредованных заболеваний
WO2007046867A2 (en) * 2005-05-19 2007-04-26 Xenon Pharmaceuticals Inc. Piperidine derivatives and their uses as therapeutic agents
DE102007025718A1 (de) * 2007-06-01 2008-12-04 Merck Patent Gmbh Pyridazinonderivate
UA103918C2 (en) 2009-03-02 2013-12-10 Айерем Элелси N-(hetero)aryl, 2-(hetero)aryl-substituted acetamides for use as wnt signaling modulators
DK2734205T3 (en) 2011-07-21 2018-06-14 Tolero Pharmaceuticals Inc Heterocyclic Protein Kinase Inhibitors
WO2013097052A1 (en) 2011-12-30 2013-07-04 Abbott Laboratories Bromodomain inhibitors
DK3442972T3 (da) 2016-04-15 2020-04-27 Abbvie Inc Bromdomænehæmmere
SG11201810366WA (en) * 2016-05-25 2018-12-28 Bayer Pharma AG 3-oxo-2,6-diphenyl-2,3-dihydropyridazine-4-carboxamides
JOP20190193A1 (ar) 2017-02-09 2019-08-08 Bayer Pharma AG ممركبات 2-أريل غير متجانس-3-أكسو-2، 3-ثنائي هيدرو بيريدازين-4-كربوكساميد لمعالجة السرطان
EP3589285A4 (en) 2017-02-28 2020-08-12 Morphic Therapeutic, Inc. INHIBITORS OF INTEGRIN (ALPHA-V) (BETA-6)
RU2769702C2 (ru) 2017-02-28 2022-04-05 Морфик Терапьютик, Инк. Ингибиторы интегрина avb6
WO2019101647A1 (en) 2017-11-21 2019-05-31 Bayer Aktiengesellschaft 2-phenylpyrimidine-4-carboxamides as ahr inhibitors
US11591311B2 (en) 2017-11-21 2023-02-28 Bayer Aktiengesellschaft 3-oxo-6-heteroaryl-2-phenyl-2,3-dihydropyridazine-4-carboxamides
US11304946B2 (en) 2017-11-21 2022-04-19 Bayer Aktiengesellschaft 2-hetarylpyrimidine-4-carboxamides as aryl hydrocarbon receptor antagonists
CA3082856A1 (en) 2017-11-21 2019-05-31 Bayer Aktiengesellschaft Sulphur substituted 3-oxo-2,3-dihydropyridazine-4-carboxamides
EP3617206A1 (en) 2018-08-29 2020-03-04 Morphic Therapeutic, Inc. Integrin inhibitors
WO2020167990A1 (en) 2019-02-12 2020-08-20 Tolero Pharmaceuticals, Inc. Formulations comprising heterocyclic protein kinase inhibitors

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB2095240A (en) * 1981-03-05 1982-09-29 Fujisawa Pharmaceutical Co Dihydropyrimidine derivatives, processes for preparation thereof and pharmaceutical composition comprising the same
JPS58140076A (ja) * 1982-02-09 1983-08-19 Mitsubishi Chem Ind Ltd ピリダジノン誘導体又はその塩類
JP3054738B2 (ja) * 1988-07-22 2000-06-19 武田薬品工業株式会社 チアゾロ［５，４―ｂ］アゼピン誘導体
IL95548A0 (en) 1989-09-15 1991-06-30 Fujisawa Pharmaceutical Co Thiazole derivatives,processes for the preparation thereof and pharmaceutical composition containing the same
DE4102024A1 (de) * 1991-01-24 1992-07-30 Thomae Gmbh Dr K Biphenylderivate, diese verbindungen enthaltende arzneimittel und verfahren zu ihrer herstellung
DE4107857A1 (de) * 1991-03-12 1992-09-17 Thomae Gmbh Dr K Cyclische harnstoffderivate, diese verbindungen enthaltende arzneimittel und verfahren zu ihrer herstellung
DE4127404A1 (de) * 1991-08-19 1993-02-25 Thomae Gmbh Dr K Cyclische iminoderivate, diese verbindungen enthaltende arzneimittel und verfahren zu ihrer herstellung

Also Published As

Publication number Publication date
CA2080748A1 (en) 1993-04-19
NO924027D0 (no) 1992-10-16
FI924687A0 (fi) 1992-10-16
US5563268A (en) 1996-10-08
US5418233A (en) 1995-05-23
DE4134467A1 (de) 1993-04-22
AU662930B2 (en) 1995-09-21
EP0537696A1 (de) 1993-04-21
NZ244766A (en) 1995-01-27
FI924687A (fi) 1993-04-19
KR930007913A (ko) 1993-05-20
ZA927994B (en) 1994-04-18
MX9205908A (es) 1993-05-01
JPH05221992A (ja) 1993-08-31
AU2706292A (en) 1993-04-22
HUT62272A (en) 1993-04-28
HU9203264D0 (en) 1992-12-28

Similar Documents

Publication Publication Date Title
NO924027L (no) Heterobiarylderivater, legemidler inneholdende disse forbindelser, og fremgangsmaate for deres fremstilling
NO940261L (no) 5-leddete heterocykler, fremgangsmåte ved fremstilling derav og legemidler som inneholder disse forbindelser
NO934501L (no) Karboksylsyrederivater, legemidler inneholdende disse forbindelser, og fremgangsmåte for deres fremstilling
NO922940L (no) Fem-leddete heterocykliske forbindelser, fremgangsmaate for deres fremstilling og legemidler inneholdende dem
MX9701305A (es) Piperidinas sustituidas novedosas utiles para el tratamiento de enfermedades alergicas.
NO972881L (no) Piperazinderivater, legemidler som inneholder disse, anvendelse derav og fremgangsmåte for deres fremstilling
NO933248L (no) Cykliske urinstoffderivater, legemidler inneholdende disse forbindelser, og fremgangsmåte for deres fremstilling
NO20023161L (no) Substituerte piperidiner, legemidler inneholdende disse forbindelser og fremgangsmåter for fremstilling av dem
NO932120L (no) Bifenylderivater, legemidler inneholdende disse, og fremgangsmaate for deres fremstilling
TW226377B (no)
EP0823423A4 (en) 1,4-DISUBSTITUTED PIPERID DERIVATIVES
NO944911L (no) Ikke-peptid-takykininreseptorantagonister
ATE242231T1 (de) Carbonyl-piperaznyl und piperidinyl derivate zur hemmung farnesyl protein transferase
HU9301155D0 (en) Methods for producing steroide derivatives and for their application in medical treatment
EP0526642A4 (no)
CA2261725A1 (en) Piperidine and piperazine derivatives and their use as muscarinic antagonists
WO1998008855A3 (en) N6 heterocyclic substituted adenosine derivatives
NO944927L (no) Fremgangsmåte for inhibering av pulmonar hypertensiv sykdom
DE69026881D1 (de) 4-Substituiertes 17-beta-(Cyclopropyl-amino)-androst-5-en-3-beta-ol und seine Derivate, verwendbar als Inhibitoren der C17-20-Lyase
NO982238D0 (no) Substituerte 4-(1H-benzimidazol-2-yl-amino)piperidiner som er anvendbare for behandling av allergiske sykdommer
RS50138B (sr) Derivati streptogramina, njihovo dobivanje i smeše koje ih sardže
NO20054168L (no) Substituerte 3-(benzoylureido)-tiofenderivater, fremgangsmate for fremstilling og anvendelse derav
DE69200284D1 (de) Verwendung von 4-(3-trifluormethylphenyl)-1,2,3,6-Tetrahydropyridinderivaten als freie Radikalfänger.
NO961333L (no) Nye pyrazolderivater som angiotensin-II-antagonister
NO20013921L (no) Heterocykliske derivater som inhibitorer av faktor Xa